Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chloropyramine→

Chloropyramine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59-32-5
Molecular formula
C16H20ClN3
Molecular weight
289.803 g/mol
Drug class
First-generation ethylenediamine antihistaminehistamine H1 receptor antagonist
Mechanism of action
Antagonises histamine H1 receptors, reducing histamine-mediated vasodilation, vascular permeability, itching and allergic symptoms. It can also produce sedative and anticholinergic effects.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis, urticaria, pruritus and other allergic reactions in countries where chloropyramine products are authorised; age, route and emergency use are product-specific

Sources: NLM MeSH — Chloropyramine · PubMed — Chloropyramine antihistamine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chloropyramine Environmental Risk Assessment (ERA) (the Chloropyramine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.